The effects of new sigma (σ) receptor ligands, PB190 and PB212, in the models predictive of antidepressant activity

Pharmacological Reports

Volumn 66, Issue 2, 2014, Pages 320-324

  Skuza, Grazyna ^a   Sadaj, Witold ^a   Kabziński, Marcin ^a   Cassano, Giuseppe ^b   Gasparre, Giuseppe ^b   Abate, Carmen ^b   Berardi, Francesco ^b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Forced swim test; Locomotor activity; Mice; Selective ligands; Tail suspension test

Indexed keywords

4 METHYL 1 [4 (6 METHOXYNAPHTHALEN 1 YL)BUTYL]PIPERIDINE; 4 METHYL 1[4 (6 METHOXY 1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL)BUTYL]PIPERIDINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMANTADINE; ANTIDEPRESSANT AGENT; BD 1063; BRADYKININ; CALCIUM ION; CATALASE; INOSITOL TRISPHOSPHATE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; NAPHTHALENE DERIVATIVE; PENTAZOCINE; PHOSPHOLIPASE C; RECEPTOR BLOCKING AGENT; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG; 4-METHYL-1-(4-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)BUTYL)PIPERIDINE; CALCIUM; ETHYLENEDIAMINE DERIVATIVE; LEAD 212; PIPERIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; TETRALIN DERIVATIVE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; C57BL 6 MOUSE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FORCED SWIM TEST; HUMAN; HUMAN CELL; IMMOBILITY TIME; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RECEPTOR AFFINITY; TAIL SUSPENSION TEST; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; IMMOBILIZATION; METABOLISM; MOTOR ACTIVITY;

AMANTADINE; ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM; ETHYLENEDIAMINES; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NAPHTHALENES; PIPERIDINES; RECEPTORS, SIGMA; TETRAHYDRONAPHTHALENES;

EID: 84899638255     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.12.002     Document Type: Article

References (37)

1. Abate C, Ferorelli S, Niso M, Lovicario C, Infantino V, Convertini P, et al. 2-Aminopyridine derivatives as potential s(2) receptor antagonists. ChemMed-Chem 2012;7:1847-57.
2. Abate C, Perrone R, Berardi F. Classes of sigma2 (s2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity. Curr Pharm Des 2012;18:938-49.
3. Abate C, Selivanova SV, Mü ller A, Krämer SD, Schibli R, Marottoli R, et al. Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the positron emission tomography (PET) imaging of s2 receptors. Eur J Med Chem 2013;69:920-30.
4. Banister SD, Kassiou M. The therapeutic potential of sigma (s) receptors for the treatment of central nervous system diseases: evaluation of the evidence. Curr Pharm Des 2012;18:884-901.
5. Berardi F, Abate C, Ferorelli S, Colabufo NA, Perrone R. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (sigma1) and sigma-2 (sigma2) receptor ligands: a review. Cent Nerv Syst Agents Med Chem 2009;9:205-19.
6. Berardi F, Abate C, Pedone MP, Colabufo NA, Contino M, Perrone R. Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the s1 receptor. J Med Chem 2005;48:8237-44. (Pubitemid 43032532)
7. Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn Schmiedebergs Arch Pharmacol 1995;351:252-60.
8. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, del Pozo E. Pharmacology of therapeutic potential of sigma 1 receptor ligands. Curr Neuropharmacol 2008;6:344-66.
9. Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG. Effector coupling mechanisms of the cloned 5-HT1A receptor. J Biol Chem 1989;264:14848-52. (Pubitemid 19237306)
10. Ferorelli S, Abate C, Pedone MP, Colabufo NA, Contino M, Perrone R, et al. Synthesis and binding assays of novel 3,3-dimethylpiperidine derivatives with various lipophilicities as s1 receptor ligands. Bioorg Med Chem 2011;19:7612-22.
11. Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 2010;127:271-82.
12. Gasparre G, Abate C, Berardi F, Cassano G. The sigma-1 receptor antagonist PB212 reduces the Ca2+-release through the inositol (1,4,5)-trisphosphate receptor in SK-N-SH cells. Eur J Pharmacol 2012;684:59-63.
13. Glossmann H, Hornung R. a-Adrenoceptors in rat brain: sodium changes the affinity of agonists for prazosin sites. Eur J Pharmacol 1980;61:407-8. (Pubitemid 10151025)
14. Hayashi T, Maurice T, Su TP. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J Pharmacol Exp Ther 2000;293:788-98. (Pubitemid 30417843)
15. Hayashi T, Su TP. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther 2003;306:718-25. (Pubitemid 36886173)
16. Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM. Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7). Br J Pharmacol 1997;122:126-32. (Pubitemid 27376029)
17. Kos T, Legutko B, Danysz W, Samoriski G, Popik P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther 2006;318:1128-36. (Pubitemid 44268318)
18. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine-and nalorphine-like drugs in the nondependent and morphinedependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-32.
19. Matsuno K, Kobayashi T, Tanaka MK, Mita S. s1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996;312:267-71. (Pubitemid 26323508)
20. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of s ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced Amnesia Brain Res. 1994 647 44-56. (Pubitemid 24154500)
21. Niso M, Abate C, Ferorelli S, Cassano G, Gasparre G, Perrone R, et al. Investigation of r receptors agonist/antagonist activity through. N-(6-methoxytetralin-1-yl)-and N-(6-methoxynaphthalen-1-yl)alkylderivatives of polymethylpiperidines. Bioorg Med Chem 2013;21:1865-9.
22. Palmer CP, Mahen R, Schnell E, Djamgoz MB, Aydar E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res 2007;67:11166-75. (Pubitemid 350248541)
23. Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004;19:2212-20. (Pubitemid 38582209)
24. Phase I Clinical Trial. Clinical Trials.gov Identifier: NCT00968656. Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 (FISO PET/CT).
25. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36. (Pubitemid 8225714)
26. Rogó z Z, Skuza G, Maj J, Danysz W. Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002;42:1024-30. (Pubitemid 34790257)
27. Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009;198:472-6.
28. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. Biol Chem 2001;276:30308.
29. Skuza G. Pharmacology of sigma (s) receptor ligands from a behavioral perspective. Curr Pharm Des 2012;18:863-74.
30. Skuza G. Potential antidepressant activity of sigma ligands. Pol J Pharmacol 2003;55:923-34. (Pubitemid 38128926)
31. Skuza G, Rogó z Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol 2006;57:217-29. (Pubitemid 44077747)
32. Skuza G, Szymaníska M, Budziszewska B, Abate C, Berardi F. Effects of PB190 and PB212, new s receptor ligands, on glucocorticoid receptor-mediated gene transcription in LMCAT cells. Pharmacol Rep 2011;63:1564-8.
33. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985;85:367-70. (Pubitemid 15123115)
34. Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998;61:247-53.
35. Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (s1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011;115:279-92.
36. Wolak M, Siwek A, Szewczyk B, Poleszak E, Pilc A, Popik P, et al. Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacol Rep 2013;65:991-7.
37. Tu Z, Xu J, Jones LA, Li S, Dumstorff C, Vangveravong S, et al. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem 2007;50:3194-204. (Pubitemid 47065968)